Allogene Therapeutics ALLO EV / sales
EV / sales at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's ev / sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's EV / sales?
- Allogene Therapeutics (ALLO) reported EV / sales of 20,538.5× in Q4 2024.
- How has Allogene Therapeutics's EV / sales changed year-over-year?
- Allogene Therapeutics's EV / sales increased by 260.1% year-over-year, from 5,703.6× to 20,538.5×.
- What is the long-term trend for Allogene Therapeutics's EV / sales?
- Over 3 years (2021 to 2024), Allogene Therapeutics's EV / sales has grown at a 951.4% compound annual growth rate (CAGR), from 17.7× to 20,538.5×.
- What does EV / sales mean?
- Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.